Macrophages feel their age in macular degeneration

Martine J. Jager1 and Caroline C.W. Klaver2,3

1Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands. 2Department of Ophthalmology and Department of Epidemiology and Biostatistics, Erasmus Medical Center, Rotterdam, The Netherlands. 3Netherlands Institute for Neuroscience, Amsterdam, Amsterdam, The Netherlands.

Macular degeneration, during which the posterior part of the eye known as the macula suffers from thinning, atrophy, and bleeding caused by abnormal angiogenesis (blood vessel formation), predominantly affects elderly adults and results in the loss of central vision. In this issue of the JCI, Kelly et al. investigate the regulation of innate immune cells, specifically macrophages, in ocular neovascularization following eye injury in mice (see the related article beginning on page 3421). They found that, as the mice aged, increased expression of IL-10 by senescent macrophages and changes in their expression of other cytokines altered the ability of these cells to restrain trauma-induced angiogenesis in the eye. These data provide insight into the effect of senescence on macrophage function and angiogenesis and have important implications for age-related diseases such as macular degeneration.

Neovascularization and the eye

The eye is a delicate structure with a finely developed blood vessel network, and any disturbances to this delicate system may lead to new blood vessel formation (angiogenesis) in areas of the eye that normally do not contain blood vessels, which may interfere with the function of the eye. In ocular diseases, abnormal blood vessel formation (neovascularization) often has a detrimental effect on vision. An important example of a disease in which the formation of abnormal blood vessels affects the eye is diabetic retinopathy, in which closure of retinal capillaries leads to ischemia, followed by the production of the proangiogenic growth factor VEGF, which induces the development of new blood vessels of an inferior type (1). Such vessels tend to bleed or grow into locations where they damage vision. Another example is age-related macular degeneration (AMD). While the central area of the retina, the macula, is normally devoid of blood vessels, in AMD, aberrant blood vessels develop in this area and destroy central vision. In response to hypoxia, these blood vessels grow from the underlying choroid through Bruch’s membrane into the subretinal space (Figure 1). This type of AMD is known as neovascular or wet AMD; together with geographic atrophy and dry AMD (a discrete, central area with degellation and breakdown of light-sensitive cells in the macula), these are the clinical forms known as AMD. Advanced AMD is a frequent cause of severe visual impairment among the elderly. The estimated prevalence of AMD is 11% in those aged 80 years and over (2), and 95% of cases of legal blindness in this age group are caused by AMD.

Macrophages and neovascularization

Macrophages have been shown to have both pro- and antiangiogenic effects following tissue injury in the eye, which suggests that their activity is carefully regulated in a complex manner, likely by local cytokines: on one hand, it has for instance been shown that macrophages are essential for removal of the hyaloid vessels; on the other hand, macrophages are necessary to

Nonstandard abbreviations used: AMD, age-related macular degeneration; FasL, Fas ligand.
Conflict of interest: The authors have declared that no conflict of interest exists.
Citation for this article: J. Clin. Invest. 117:3182–3184 (2007). doi:10.1172/JCI34070.
stimulate inflammation-induced neovascularization (3, 4). Macrophages thus play a dual role, and have recently been found to be physically associated with growing as well as regressing vessels (5). It has also been reported that age can influence angiogenesis (6). Therefore, in their study in this issue of the *JCI*, Kelly et al. (7) sought to further investigate the influence of macrophages on blood vessel formation in the eye, specifically the factors, age or otherwise, that regulate the pro- or antiangiogenic nature of macrophage function during neovascularization of the eye.

In order to study blood vessel formation in the retina, Kelly et al. (7) used a previously developed animal model that possesses a clinical phenotype much like that observed in diabetic retinopathy: laser-induced eye injury causes retinal ischemia in the murine eye, which is subsequently followed by choroidal neovascularization (6). Vessel growth can be examined via several imaging techniques, and this growth can then be manipulated. Kelly et al. used a laser to induce rupture of Bruch’s membrane in mice less than 2 months of age or older than 18 months of age. Evaluation of the angiogenic response 7 days after injury revealed that, surprisingly, the older mice had significantly more macrophage-rich neovascularization compared with the young mice, suggesting that their antiangiogenic responses were impaired.

As prior studies showed that macrophages play a role in neovascularization after laser-induced injury (8, 9), and as histology of laser-induced injuries showed massive infiltration of the injury site with macrophages (10), Kelly et al. sought to determine whether there was any functional difference between macrophages from young and older mice with respect to their ability to inhibit angiogenesis (7). The authors isolated macrophages from young or old mice and injected these cells into the eyes of old mice on the day of laser-induced injury. Macrophages from the young mice inhibited the subsequent choroidal neovascularization; however, macrophages from the old mice did not, which indicates that macrophages from young mice had a dominant effect, as they were able to overcome the lack of inhibition of angiogenesis that was typical in older mice. Surprisingly, injection of macrophages incubated in IL-10 did not have the same dramatic effect, although they appeared to inhibit angiogenesis slightly.

The authors looked to the cytokine profile of the macrophages in young versus old mice for clues to the potential differences in macrophage activity (7). They found that macrophage-rich choroidal neovascularization lesions in the older mice had significantly reduced expression of IL-12, TNF-α, and Fas ligand (FasL) and high IL-10 expression compared with young mice. This observation was particularly

---

**Figure 1**

Role of normal versus senescent macrophages in ocular neovascularization. In this issue, Kelly et al. (7) report that following laser-induced injury of the retina, macrophage infiltration occurs in both young (<2 months) and old (>18 months) mice. However, this macrophage infiltration is associated with neovascularization in older mice only. RT-PCR analyses of macrophages isolated from the retinas of older mice revealed lower expression levels of TNF-α, FasL, and IL-6 than in macrophages in the retinas of younger mice. An increase in IL-10 expression was observed in the retinas of all mice, although baseline levels were higher in old mice. These data suggest that as the mice age, increased IL-10 expression and altered cytokine expression limits the ability of senescent macrophages to regulate injury-induced neovascularization in the eye. The authors’ findings provide insight into the role of macrophages during neovascularization in AMD.
investing given that this research group had previously demonstrated that IL-10–/– mice have a reduced angiogenic response following laser-induced eye injury (6).

Finally, incubating endothelial cells in vitro with macrophages from old and young mice again showed a differential effect, with the macrophages from old mice stimulating the outgrowth of endothelial cells and the macrophages from young mice inhibiting endothelial cell growth (7).

**Age matters**

The study by Kelly et al. (7) shows us that age matters. Older mice were not able to inhibit blood vessel growth, and this was linked to a loss of some intracellular cytokines, a loss of expression of FasL, and an increase in the production of IL-10. It may well be that similar changes occur in humans. The loss of expression of FasL, and an increase in inflammatory cytokines, has been linked to the outgrowth of endothelial cells, and this was linked to the macrophages in ocular tumors (13). Macrophages in ocular tumors

Macrophages may also influence the behavior of tumors. Human intraocular tumors have been shown to contain high numbers of macrophages, and a significant association has been observed between the number of macrophages and the number of blood vessels in such tumors (14). In addition, both parameters were associated with an increased chance of dying as a result of tumor metastases. Because intraocular melanomas occur with higher incidence in older people, it may also be an influx of “old” macrophages stimulates blood vessel formation in these tumors. Blood vessels are critical for tumor metastasis, because tumors spread hematogenously. Intriguingly, similar to the earlier findings of these authors demonstrating that depletion of macrophages in young mice induced neovascularization (6), depletion of macrophages in murine eyes prior to tumor cell implantation did not stop tumor growth (15). As far as we are aware, no studies have been undertaken on the effect of age on tumor growth in an experimental murine intraocular tumor model.

**Conclusions**

The description by Kelly et al. (7) of the different angiogenic properties of macrophages in young and old mice helps us to better understand why certain diseases have a tendency to occur specifically in the elderly. As the production of cytokines such as IL-10 play a role in angiogenesis, therapeutic avenues that change the production of such cytokines might be investigated. As genetic studies may identify those individuals at higher risk of developing AMD when they age, developing early intervention measures may contribute to the prevention of blindness in the elderly.

Address correspondence to: M.J. Jager, Department of Ophthalmology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands. Phone: 31-71-5263097; Fax: 31-71-5248222; E-mail: m.j.jager@lumc.nl.